Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer
A Phase III Randomized Study of 5-Fluorouracil, Mitomycin-C, and Radiotherapy Versus 5-Fluorouracil, Cisplatin, and Radiotherapy in Carcinoma of the Anal Canal
Sponsor: Cancer and Leukemia Group B
Listed as NCT00003596, this PHASE3 trial focuses on Anal Cancer and remains completed. Sponsored by Cancer and Leukemia Group B, it has been updated 8 times since 1998, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
May 2023 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — May 2023 [monthly]
Completed PHASE3
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Oct 1998
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Cancer and Leukemia Group B
- Eastern Cooperative Oncology Group
- National Cancer Institute (NCI)
- North Central Cancer Treatment Group
- Radiation Therapy Oncology Group
- SWOG Cancer Research Network
For direct contact, visit the study record on ClinicalTrials.gov .